Features

The US Supreme Court heard oral arguments in cases involving the legality of reciprocal tariffs, country-by-country tariffs imposed through a series of trade deals and executive actions. Is tariff relief a possibility or not?

Which biologics have received approval by FDA’s Center for Drug Evaluation and Research thus far in 2025, and how are they positioned in the market? What other market contenders loom in the industry’s pipeline?

Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?

Partnering deals and MA& among the large bio/pharma companies and smaller companies not only reflect strategic decisions by the bio/pharma majors to build their product portfolios, but also put these smaller companies on the industry map. Which companies are making the mark in 2025?

Roche released its earnings for the first nine months of 2025, which saw its pharmaceutical revenues increase by 9% at constant exchange rates. Its top five growth drivers – Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus – achieved total sales of nearly $20 billion. Will momentum continue?

mRNA technology was lifted into commercial success during the pandemic, with two major mRNA vaccines, Pfizer’s/BioNTech’s Comirnaty and Moderna’s Spikevax. With that market closing, where does the mRNA pipeline stand? Is oncology the next wave?

The biotech industry stands at a crossroads. The interplay between innovation, policy changes, and pricing challenges will shape the future of biotech, influencing how companies navigate funding, research, and product development.

How are small-molecule drugs faring in new drug approvals by FDA thus far in 2025? Where does the industry stand now and comparative to recent trends? DCAT Value Chain Insights looks at the products and companies.

FDA has introduced a new pilot program to prioritize abbreviated new drug applications for generic drugs that use US-based manufacturing and testing, the latest in a series of moves by the Administration to incentivize US-based manufacturing.

Antibody drug conjugates (ADCs) are a growing modality in the oncology drug market. Bispecific ADCs are an emerging subset of ADCs with several investigational drug candidates advancing. The latest developments in the ADC drug market.